. Author manuscript; available in PMC: 2017 Aug 15.

Published in final edited form as: Eur J Clin Pharmacol. 2011 Dec 30;68(5):723–733. doi: 10.1007/s00228-011-1200-7

Table 2. Steady state PK parameters of nilotinib in the full PK cohort.

	C_min (ng/mL)	C_max (ng/mL)	AUC_0–tlast (ng∙h/mL)	T_max^a (h)	CL/F (L/h)
Nilotinib 300 mg twice daily (n=16)^b
Geometric mean (CV%)	1,123 (64.1)	1,360 (58.6)	11,865 (56.8)	2.00 (0.00, 7.95)	25.28 (56.8)
Nilotinib 400 mg twice daily (n=15)^b
Geometric mean (CV%)	1,239 (51.9)	1,595 (47.0)	13,656 (51.3)	2.00 (0.00, 7.95)	29.3 (51.3)

T_max values are presented as median (range).

Full PK samples were collected from 17 patients in each arm, 3 of whom (1 in the 300 mg twice-daily arm and 2 in the 400 mg twice-daily arm) did not have sufficient data points for the calculation of full PK parameters and were excluded from the analyses shown in this table.

CV, coefficient of variation; T_max, time to maximum concentration.